Sosei closer to releasing first ever Japanese ECP

20 July 2008

Japanese biopharmaceutical company Sosei has completed a Phase III trial in Japan for NorLevo (levonorgestrel), which could become the first emergency contraceptive pill to enter its domestic market.

The clinical study was designed to evaluate the safety and prevented pregnancy rate of the pill in Japanese adult female subjects who require emergency contraception. The dosing is started within 72 hours after unprotected sexual intercourse. No serious adverse events were noted during the trial.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight